Focal therapy for prostate cancer: Pathologic basis
Current Opinion in Urology, ISSN: 0963-0643, Vol: 19, Issue: 2, Page: 161-167
2009
- 15Citations
- 11Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations15
- Citation Indexes15
- CrossRef15
- 14
- Captures11
- Readers11
- 11
Review Description
Purpose of review To summarize pathologic features of low-volume, low-risk prostate cancer relevant to the development of patient selection criteria and treatment strategies for focal therapy of prostate cancer, as an alternative to whole-gland radical treatments. Recent findings Prostate cancer characteristically presents as a multifocal lesion within the prostate gland. Diagnosis of prostate cancer at an early stage has led to a recognition of subsets of patients whose disease may be either unifocal or multifocal, yet is unilateral or of small aggregate volume. Parenchyma-preserving partial-gland ablation may become a potentially feasible option in future treatment of early-stage, localized prostate cancer. Conclusion Even for moderately selective protocols such as hemiablation, however, appropriate patient selection will be challenging because of the imperfect correlation among unifocality, unilaterality, low volume and low grade. Extended multicore biopsy protocols under imaging guidance may be required to map the tumor process with sufficient accuracy for treatment planning. Further research in molecular determinants and more precise imaging techniques should be pursued to optimize selection and treatment. © 2009 Wolters Kluwer Health|Lippincott Williams & Wilkins.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=61349100767&origin=inward; http://dx.doi.org/10.1097/mou.0b013e328323f62b; http://www.ncbi.nlm.nih.gov/pubmed/19188770; http://journals.lww.com/00042307-200903000-00009; http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00042307-200903000-00009; https://dx.doi.org/10.1097/mou.0b013e328323f62b; https://insights.ovid.com/ShowUpgradeBrowserMessage
Ovid Technologies (Wolters Kluwer Health)
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know